Limits...
Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus

The effect of oral Bromelain treatment on BAL Lymphocytes. After 3 OVA aerosol exposures, there was a significant increase in the percentages of CD19 + B cells (A) CD8 + T cells (B) and CD4 + T cells (C) in the BAL of AAD mice, as compared to naïve controls. Oral Bromelain treatment significantly reduced CD19 + B cells (P ≤ 0.00003; A), and CD8 + T cells (P ≤ 0.00002; B). There was no change in the percentages of CD4 + T cells in the BAL between AAD and Bromelain treated AAD mice (P ≤ 0.095; C). Statistical comparisons were made by un-paired t-test, *P ≤ 0.0001; Data represent means + SEM, n = 8 animals per group.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC2249734&req=5

Figure 3: The effect of oral Bromelain treatment on BAL Lymphocytes. After 3 OVA aerosol exposures, there was a significant increase in the percentages of CD19 + B cells (A) CD8 + T cells (B) and CD4 + T cells (C) in the BAL of AAD mice, as compared to naïve controls. Oral Bromelain treatment significantly reduced CD19 + B cells (P ≤ 0.00003; A), and CD8 + T cells (P ≤ 0.00002; B). There was no change in the percentages of CD4 + T cells in the BAL between AAD and Bromelain treated AAD mice (P ≤ 0.095; C). Statistical comparisons were made by un-paired t-test, *P ≤ 0.0001; Data represent means + SEM, n = 8 animals per group.

Mentions: As compared with naïve and naïve bromelain-treated mice, AAD mice displayed significant increases in the percentage of BAL CD4+, CD8+ and CD19+ lymphocytes (Fig. 3). Bromelain-treated AAD mice resulted in significant reductions in CD8+ (19 ± 1 versus 9 ± 2; P ≤ 0.002), and CD19+ lymphocytes (2.4 ± 0.3 versus 2.4 ± 0.2; P ≤ 0.002) when compared with AAD-saline-treated mice. No significant changes in CD4+ lymphocytes were noted in similar comparisons.Figure 3.


Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma.

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS - Evid Based Complement Alternat Med (2008)

The effect of oral Bromelain treatment on BAL Lymphocytes. After 3 OVA aerosol exposures, there was a significant increase in the percentages of CD19 + B cells (A) CD8 + T cells (B) and CD4 + T cells (C) in the BAL of AAD mice, as compared to naïve controls. Oral Bromelain treatment significantly reduced CD19 + B cells (P ≤ 0.00003; A), and CD8 + T cells (P ≤ 0.00002; B). There was no change in the percentages of CD4 + T cells in the BAL between AAD and Bromelain treated AAD mice (P ≤ 0.095; C). Statistical comparisons were made by un-paired t-test, *P ≤ 0.0001; Data represent means + SEM, n = 8 animals per group.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC2249734&req=5

Figure 3: The effect of oral Bromelain treatment on BAL Lymphocytes. After 3 OVA aerosol exposures, there was a significant increase in the percentages of CD19 + B cells (A) CD8 + T cells (B) and CD4 + T cells (C) in the BAL of AAD mice, as compared to naïve controls. Oral Bromelain treatment significantly reduced CD19 + B cells (P ≤ 0.00003; A), and CD8 + T cells (P ≤ 0.00002; B). There was no change in the percentages of CD4 + T cells in the BAL between AAD and Bromelain treated AAD mice (P ≤ 0.095; C). Statistical comparisons were made by un-paired t-test, *P ≤ 0.0001; Data represent means + SEM, n = 8 animals per group.
Mentions: As compared with naïve and naïve bromelain-treated mice, AAD mice displayed significant increases in the percentage of BAL CD4+, CD8+ and CD19+ lymphocytes (Fig. 3). Bromelain-treated AAD mice resulted in significant reductions in CD8+ (19 ± 1 versus 9 ± 2; P ≤ 0.002), and CD19+ lymphocytes (2.4 ± 0.3 versus 2.4 ± 0.2; P ≤ 0.002) when compared with AAD-saline-treated mice. No significant changes in CD4+ lymphocytes were noted in similar comparisons.Figure 3.

Bottom Line: Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models.Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P </= 0.01), reduction in BAL eosinophils (P </= 0.02) and IL-13 concentrations (P </= 0.04) as compared with PBS controls.These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in this murine model of asthma and bromelain may also be effective in human conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.

ABSTRACT
Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to have immunomodulatory effects in a variety of immune system models. The purpose of the present study was to determine the effects of orally administered bromelain in an ovalbumin (OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD, female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered saline)PBS or 200 mg/kg bromelain in PBS, twice daily for four consecutive days, beginning 1 day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity, bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung histology were compared between treatment groups. Oral bromelain-treatment of AAD mice demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P

No MeSH data available.


Related in: MedlinePlus